Neurologic manifestations in 1760 COVID-19 patients admitted to Papa Giovanni XXIII Hospital, Bergamo, Italy.
Altered mental status
COVID-19
Cerebrovascular diseases
Infectious diseases
Peripheral neuropathies
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
21
07
2020
accepted:
29
09
2020
revised:
22
09
2020
pubmed:
8
10
2020
medline:
24
6
2021
entrez:
7
10
2020
Statut:
ppublish
Résumé
Evidences from either small series or spontaneous reporting are accumulating that SARS-CoV-2 involves the Nervous Systems. The aim of this study is to provide an extensive overview on the major neurological complications in a large cohort of COVID-19 patients. Retrospective, observational analysis on all COVID-19 patients admitted from February 23rd to April 30th, 2020 to ASST Papa Giovanni XXIII, Bergamo, Italy for whom a neurological consultation/neurophysiological assessment/neuroradiologic investigation was requested. Each identified neurologic complication was then classified into main neurologic categories. Of 1760 COVID-19 patients, 137 presented neurologic manifestations that manifested after COVID-19 symptoms in 98 pts and was the presenting symptom in 39. Neurological manifestations were classified as: (a) cerebrovascular disease [53 pts (38.7%)] including 37 ischemic and 11 haemorrhagic strokes, 4 transient ischemic attacks, 1 cerebral venous thrombosis; (b) peripheral nervous system diseases [31 (22.6%)] including 17 Guillain-Barrè syndromes; (c) altered mental status [49 (35.8%)] including one necrotizing encephalitis and 2 cases with RT-PCR detection of SARS-Cov-2 RNA in CSF; (d) miscellaneous disorders, among whom 2 patients with myelopathy associated with Ab anti-SARS-CoV-2 in CSF. Patients with peripheral nervous system involvement had more frequently severe ARDS compared to patients with cerebrovascular disease (87.1% vs 42%; difference = 45.1% 95% CI 42.0-48.2; χ This study confirms that involvement of nervous system is common in SARS-CoV-2 infection and offers clinicians useful information for prevention and prompt identification in order to set the adequate therapeutic strategies.
Identifiants
pubmed: 33026520
doi: 10.1007/s00415-020-10251-5
pii: 10.1007/s00415-020-10251-5
pmc: PMC7539268
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2331-2338Références
Case Rep Neurol Med. 2016;2016:3502683
pubmed: 27239356
Lancet Psychiatry. 2020 Oct;7(10):875-882
pubmed: 32593341
Neurol Neuroimmunol Neuroinflamm. 2020 Apr 29;7(4):
pubmed: 32350026
Cochrane Database Syst Rev. 2006 Jan 25;(1):CD002063
pubmed: 16437439
JAMA. 2020 Apr 14;323(14):1335
pubmed: 32181795
N Engl J Med. 2020 Jun 4;382(23):2268-2270
pubmed: 32294339
Int J Infect Dis. 2020 May;94:55-58
pubmed: 32251791
Lancet Neurol. 2020 May;19(5):383-384
pubmed: 32246917
Ann Neurol. 1998 Nov;44(5):780-8
pubmed: 9818934
Biomed J. 2020 Aug;43(4):328-333
pubmed: 32387617
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
J Neurol. 2004 Oct;251(10):1227-31
pubmed: 15503102
Brain. 2020 Oct 1;143(10):3104-3120
pubmed: 32637987
N Engl J Med. 2020 Jun 25;382(26):2574-2576
pubmed: 32302082
Ann Intern Med. 2020 Jun 2;172(11):726-734
pubmed: 32282894
Neurol Neuroimmunol Neuroinflamm. 2020 Jun 10;7(5):
pubmed: 32522767
Infection. 2015 Aug;43(4):495-501
pubmed: 25600929